PDCD1 and neoplasm: The therapeutic blockade of the PD-1/PD-L1 pathway using monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, has shown substantial efficacy in enhancing anti-tumor immunity [52].